NetworkNewsBreaks

TuesdayJan 30, 2024 1:47 pm

NetworkNewsBreaks — Jeffs’ Brands Ltd. (NASDAQ: JFBR, JFBRW) Closes on $7.275M Private Placement

Jeffs’ Brands Ltd (NASDAQ: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, has closed on its recently announced private placement. The placement, which closed on Jan. 29, 2024, was with specific institutional investors. According to the announcement, gross cash proceeds from the placement totaled $7.275 million before deductions and expenses. Jeffs’ Brands anticipates using the net proceeds for working capital and general corporate purposes; funds could also be used for acquisitions, although the company has no pending acquisitions at this time. The company observes that, in connection with the private placement, it issued 2,704,461 units and prefunded…

Continue Reading

TuesdayJan 30, 2024 1:43 pm

NetworkNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Expands Sales Dominican Republic, Caribbean Markets with Grupo Cavel Order

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has received a vehicle order from Grupo Cavel for the sale of EVs its Electric Motors dealerships located in the Dominican Republic and Caribbean. The order was for 20 CAMPUS EV cargo vans. According to the announcement, Grupo Cavel plans to order additional vehicles and will be establishing a sales and service distribution channel for Mullen’s lineup of commercial EVs in the two countries. Grupo Cavel is a key retail automotive group in the Dominican Republic and has existing relationships in vehicle sales, distribution, warranty and servicing throughout the Caribbean.…

Continue Reading

TuesdayJan 30, 2024 1:31 pm

NetworkNewsBreaks – IBN, BioMedWire to Serve as Official Media Partners for BioPharma Nexus Events

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, has announced its media collaboration with BioPharma Nexus for upcoming events in 2024. BioMedWire, a specialized communications platform dedicated to the life sciences sector and a vital component of IBN’s Dynamic Brand Portfolio, will also serve as an official media partner for the events. Renowned for its expertise in life sciences, BioPharma Nexus organizes industry leading events covering clinical trials, drug discovery, medical affairs, pharmaceutical supply chains and related logistics. The events are tailored to optimize productivity and enhance global networking opportunities. “Rapid advancements in medical solutions, novel business structures, digital…

Continue Reading

TuesdayJan 30, 2024 1:23 pm

NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY) to Implement 1-for-40 Reverse Split

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, has announced a 1-for-40 reverse split of its common stock. The reverse split will go into effect tomorrow, Jan. 31, 2024. According to the company, its common stock will trade on a post-split basis at the beginning of the trading day on Jan. 31, under its existing trading symbol: SIGY. The announcement included pertinent stockholder information regarding the upcoming split. “The reverse stock split is intended to increase the market price per share of the company’s common stock to gain compliance with the minimum bid listing requirement of the NASDAQ Capital…

Continue Reading

TuesdayJan 30, 2024 12:52 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). The application covers HYPER-H23-1, the company’s upcoming planned U.S. phase 1b hypertension clinical trial of DehydraTECH-CBD. According to the announcement, the company had a successful pre-IND meeting with FDA officials. Following the guidance provided in that meeting regarding the development and filing of the IND, the company submitted the application on Jan. 29, 2024. The company will now wait 30 calendar days before initiating any clinical trials, in compliance with FDA guidelines.…

Continue Reading

TuesdayJan 30, 2024 12:19 pm

NetworkNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Expands Sales of Wearable Alcohol Detection Devices to Australia, New Zealand

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, has entered into an international channel partnership to begin sales in Australia and New Zealand for its SOBRsure(TM) platform. The partnership is with Drug Testing Business Success, the region's leading drug- and alcohol-testing service provider. According to the announcement, Drug Testing Business Success has impressive experience in the transdermal alcohol detection industry and plans to distribute SOBRsure through a coalition of suppliers and a dedicated e-commerce website focusing on the behavioral health and justice sectors. The partnership included a 90-day proof-of-concept period; SOBRsure is now available for sale and is in…

Continue Reading

TuesdayJan 30, 2024 10:48 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Names New Board Member, Reports on Corporate Updates

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has appointed Dr. Sanjiv Chopra to its board of directors. According to the announcement. Chopra will be replacing Nitin Kaushal, who resigned from his position. A professor of medicine and former faculty dean for continuing medical education at Harvard Medical School, Dr. Sanjiv Chopra, MD, now serves as a Marshall Wolf Distinguished Clinician Educator at Brigham and Women's Hospital. A renowned speaker and author with more than 170 publications and 10 books to his credit, Chopra also serves…

Continue Reading

TuesdayJan 30, 2024 10:12 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of the company. The offering is comprised of the purchase and sale of 13,333,334 shares of common stock (or common stock equivalents in lieu thereof); the stock is offered at a purchase price of $0.30 per share. In addition, CNSP agreed to issue Series A warrants…

Continue Reading

MondayJan 29, 2024 2:36 pm

NetworkNewsBreaks – IBN, InvestorWire to Generate Increased Interest for Quant Strats

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announced that its InvestorWire (“IW”) was selected by Alpha Events as the official newswire for Quant Strats, the premier event for quantitative investment thought leaders. The conference is slated to take place at Quorum by Convene in New York City on March 12, 2024. IBN will serve as the official corporate communications firm for the event. Quant Strats, renowned for assembling a unique audience of specialists, including data teams, quant traders and portfolio managers, features industry speakers with unique insights and perspectives, placing a strong emphasis on real-life applications of the latest technological developments.…

Continue Reading

MondayJan 29, 2024 12:49 pm

NetworkNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Inks Grain-Management Distribution Agreement with Poppe Enterprises

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has entered a signed distribution agreement with Poppe Enterprises LLC. A distributor and pest-management company focused on the grain-management market, Poppe Enterprises serves Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa and Colorado. Poppe Enterprises will be a stocking distributor for SNES’s Evolve(TM) soft bait and has placed an initial stocking order. Evolve is designed to address the fundamental issue of rodent overpopulation by focusing on the rapid reproduction of rats; the product controls the population by reducing or eliminating the fertility of rats, rather than trying to keep up with the…

Continue Reading